KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Long-Term Debt Issuances (2020 - 2025)

Royalty Pharma's Long-Term Debt Issuances history spans 3 years, with the latest figure at -$1.5 billion for Q4 2024.

  • For Q4 2024, Long-Term Debt Issuances changed N/A year-over-year to -$1.5 billion; the TTM value through Dec 2025 reached -$1.5 billion, changed 0.0%, while the annual FY2025 figure was $1.3 billion, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q4 2024 was -$1.5 billion at Royalty Pharma, down from $1.3 billion in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $6.0 billion in Q1 2020 and bottomed at -$1.5 billion in Q4 2024.
  • The 3-year median for Long-Term Debt Issuances is $3.6 billion (2020), against an average of $2.9 billion.
  • The largest YoY upside for Long-Term Debt Issuances was 78.25% in 2021 against a maximum downside of 78.25% in 2021.
  • A 3-year view of Long-Term Debt Issuances shows it stood at $5.9 billion in 2020, then tumbled by 78.25% to $1.3 billion in 2021, then tumbled by 215.61% to -$1.5 billion in 2024.
  • Per Business Quant, the three most recent readings for RPRX's Long-Term Debt Issuances are -$1.5 billion (Q4 2024), $1.3 billion (Q3 2021), and $5.9 billion (Q3 2020).